Literature DB >> 26549996

Pancreatic cancer and SBRT: A new potential option?

Carla Hajj1, Karyn A Goodman1.   

Abstract

Local control remains a major issue for patients with unresectable, locally advanced pancreatic cancer (LAPC). The role of radiation therapy in the management of LAPC represents an area of some controversy. Stereotactic body radiotherapy is an emerging treatment option for LAPC as it can provide a therapeutic benefit with significant advantages for patients' quality of life over standard conventional chemoradiation. The objective of this review is to present the rationale for stereotactic body radiotherapy in LAPC, as well as to discuss the potential limitations and caveats of the currently available studies.

Entities:  

Keywords:  Local control; Pancreatic cancer; Stereotactic body radiotherapy

Year:  2015        PMID： 26549996      PMCID： PMC4597084          DOI： 10.1016/j.rpor.2015.05.008

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN： 1507-1367


  41 in total

1.  Pain as a predictor of outcome in patients with operable pancreatic carcinoma.

Authors:  D P Kelsen; R Portenoy; H Thaler; Y Tao; M Brennan
Journal:  Surgery       Date:  1997-07       Impact factor: 3.982

2.  Stereotactic body radiation therapy for nonresectable tumors of the pancreas.

Authors:  Kush Goyal; Douglas Einstein; Rafael A Ibarra; Min Yao; Charles Kunos; Rod Ellis; James Brindle; Deepjot Singh; Jeffrey Hardacre; Yuxia Zhang; Jeffrey Fabians; Gary Funkhouser; Mitchell Machtay; Juan R Sanabria
Journal:  J Surg Res       Date:  2011-09-05       Impact factor: 2.192

3.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

4.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

5.  Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins.

Authors:  Jean-Claude M Rwigema; Dwight E Heron; Simul D Parikh; Herbert J Zeh; James A Moser; Nathan Bahary; Karlotta Ashby; Steven A Burton
Journal:  J Gastrointest Cancer       Date:  2012-03

6.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

7.  Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

Authors:  Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-05       Impact factor: 7.038

8.  Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas.

Authors:  Chris E Lominska; Keith Unger; Nadim M Nasr; Nadim Haddad; Greg Gagnon
Journal:  Radiat Oncol       Date:  2012-05-18       Impact factor: 3.481

9.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

10.  SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.

Authors:  Angelo Tozzi; Tiziana Comito; Filippo Alongi; Pierina Navarria; Cristina Iftode; Pietro Mancosu; Giacomo Reggiori; Elena Clerici; Lorenza Rimassa; Alessandro Zerbi; Antonella Fogliata; Luca Cozzi; Stefano Tomatis; Marta Scorsetti
Journal:  Radiat Oncol       Date:  2013-06-21       Impact factor: 3.481
View more
  10 in total

1.  Stereotactic Body Radiation Therapy: A useful weapon in anticancer treatment.

Authors:  M Scorsetti
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-23

2.  A Novel Respiratory Motion Perturbation Model Adaptable to Patient Breathing Irregularities.

Authors:  Amy Yuan; Jie Wei; Carl P Gaebler; Hailiang Huang; Devin Olek; Guang Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-09-03       Impact factor: 7.038

3.  Individually optimized stereotactic radiotherapy for pancreatic head tumors: A planning feasibility study.

Authors:  Milly Buwenge; Savino Cilla; Alessandra Guido; Lucia Giaccherini; Gabriella Macchia; Francesco Deodato; Silvia Cammelli; Francesco Cellini; Gian C Mattiucci; Vincenzo Valentini; Markus Stock; Alessio G Morganti
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-28

4.  An evaluation of motion mitigation techniques for pancreatic SBRT.

Authors:  Warren G Campbell; Bernard L Jones; Tracey Schefter; Karyn A Goodman; Moyed Miften
Journal:  Radiother Oncol       Date:  2017-05-29       Impact factor: 6.280

5.  Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway.

Authors:  J Xue; W Zhu; J Song; Y Jiao; J Luo; C Yu; J Zhou; J Wu; M Chen; W-Q Ding; J Cao; S Zhang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

6.  An Evaluation of Total Internal Motions of Locally Advanced Pancreatic Cancer during SABR Using Calypso® Extracranial Tracking, and Its Possible Clinical Impact on Motion Management.

Authors:  Hrvoje Kaučić; Domagoj Kosmina; Dragan Schwarz; Adlan Čehobašić; Vanda Leipold; Ivo Pedišić; Mihaela Mlinarić; Matea Lekić; Hrvoje Šobat; Andreas Mack
Journal:  Curr Oncol       Date:  2021-11-11       Impact factor: 3.677

7.  Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Using Optical Surface Management System - AlignRT as an Optical Body Surface Motion Management in Deep Breath Hold Patients: Results from a Single-Arm Retrospective Study.

Authors:  Hrvoje Kaučić; Domagoj Kosmina; Dragan Schwarz; Andreas Mack; Adlan Čehobašić; Vanda Leipold; Asmir Avdićević; Mihaela Mlinarić; Matea Lekić; Karla Schwarz; Marija Banović
Journal:  Cancer Manag Res       Date:  2022-07-12       Impact factor: 3.602

Review 8.  Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe.

Authors:  Domenico Albano; Massimo Benenati; Antonio Bruno; Federico Bruno; Marco Calandri; Damiano Caruso; Diletta Cozzi; Riccardo De Robertis; Francesco Gentili; Irene Grazzini; Giuseppe Micci; Anna Palmisano; Carlotta Pessina; Paola Scalise; Federica Vernuccio; Antonio Barile; Vittorio Miele; Roberto Grassi; Carmelo Messina
Journal:  Insights Imaging       Date:  2021-06-10

9.  A new technique for minimally invasive irreversible electroporation of tumors in the head and body of the pancreas.

Authors:  David Stillström; Henrik Nilsson; Michaela Jesse; Matthias Peterhans; Eduard Jonas; Jacob Freedman
Journal:  Surg Endosc       Date:  2016-08-29       Impact factor: 4.584

10.  Automated treatment planning as a dose escalation strategy for stereotactic radiation therapy in pancreatic cancer.

Authors:  Savino Cilla; Anna Ianiro; Carmela Romano; Francesco Deodato; Gabriella Macchia; Pietro Viola; Milly Buwenge; Silvia Cammelli; Antonio Pierro; Vincenzo Valentini; Alessio G Morganti
Journal:  J Appl Clin Med Phys       Date:  2020-10-16       Impact factor: 2.243
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.